ArticleOncoTargets and therapy2017
microRNA-130a is an oncomir suppressing the expression of
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test.Journal of translational medicine · 2019Pooled it
- Establishment of a 7-microRNA prognostic signature and identification of hub target genes in colorectal carcinoma.Translational cancer research · 2022Article
- Oncogenic role of MiR-130a in oral squamous cell carcinoma.Scientific reports · 2021Article
- Collapsin response mediator protein 4 enhances the radiosensitivity of colon cancer cells through calcium‑mediated cell signaling.Oncology reports · 2021Article
- Down-Regulated miR-130a/b Attenuates Rhabdomyosarcoma ProliferationFrontiers in molecular biosciences · 2021Article
- Plasma-Derived Exosomal microRNA-130a Serves as a Noninvasive Biomarker for Diagnosis and Prognosis of Oral Squamous Cell Carcinoma.Journal of oncology · 2021Article
- A three serum miRNA panel as diagnostic biomarkers of radiotherapy-related metastasis in non-small cell lung cancer.Oncology letters · 2020Article
- ARPP-19 Mediates Herceptin Resistance via Regulation of CD44 in Gastric Cancer.OncoTargets and therapy · 2020Article
- MicroRNA replacement therapy in cancer.Journal of cellular physiology · 2019Review
- Up-regulation of tumor necrosis factor-α pathway survival genes and of the receptor TNFR2 in gastric cancer.World journal of gastrointestinal oncology · 2019Article
- The MYB/miR-130a/NDRG2 axis modulates tumor proliferation and metastatic potential in salivary adenoid cystic carcinoma.Cell death & disease · 2018Article
- Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs.International journal of molecular sciences · 2017Review
- microRNAs Promoting Growth of Gastric Cancer Xenografts and Correlation to Clinical Prognosis.Cancer genomics & proteomicsReview
Corrections and comments
- Retraction · 2023-09-05Author Unresponsive · Concerns/Issues about Data · Duplication of/in Image · Original Data and/or Images not Provided and/or not Available · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is one of the most common causes of death worldwide, although its incidence has steadily declined in recent years. There is strong evidence that aberrantly expressed microRNAs (miRNAs) are involved in gastric cancer tumorigenesis. Furthermore,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.